F-18-labeled radiopharmaceuticals for PET in oncology, excluding FDG

Authors
Varagnolo, L Stokkel, MPM Mazzi, U Pauwels, EKJ
Citation
L. Varagnolo et al., F-18-labeled radiopharmaceuticals for PET in oncology, excluding FDG, NUCL MED BI, 27(2), 2000, pp. 103-112
Citations number
134
Categorie Soggetti
Medical Research Diagnosis & Treatment
Journal title
NUCLEAR MEDICINE AND BIOLOGY
ISSN journal
09698051 → ACNP
Volume
27
Issue
2
Year of publication
2000
Pages
103 - 112
Database
ISI
SICI code
0969-8051(200002)27:2<103:FRFPIO>2.0.ZU;2-W
Abstract
This article reviews possible use of F-18-labelled radiopharmaceuticals in oncology with positron emission tomography. The characteristics of various F-18-labelled compounds are proteins and peptides, those that bind to recep tors, agents to assess hypoxia, and agents to evaluate gene therapy are hig hlighted. Furthermore, different F-18-labelled tissue specific agents are i ndicated for the detection and monitoring of various malignancies: melanoma , brain tumours, breast cancer, prostate cancer and colorectal cancer. F-18 -fluorodeoxyglucose has been excluded from this summary. NUCL MED BIOL 27;2 :103-112, 2000. (C) 2000 Elsevier Science Inc. All rights reserved.